Skip to main content
. 2022 Apr 22;21(15):1590–1598. doi: 10.1080/15384101.2022.2058839

Figure 3.

Figure 3.

KLF7 was targeted by miR-1301-3p. (a) The Venn diagram of potential mRNAs possessing the binding site with miR-1301-3p on the microT, PicTar, miRmap websites under the condition of pan-cancer ≥8. (b) The enrichment of KLF7, HIPK3, SUSD6, FOXC1 and AKAP2 for miR-1301-3p was examined by RNA pull down assay. (c) The KLF7 level in HG-stimulated ARPE-19 cells was detected by RT-qPCR and western blotting assays. (d) The binding site and relationship between KLF7 and miR-1301-3p were examined using a luciferase reporter assay. (e-f) KLF7 level in ARPE-19 cells with overexpressed miR-1301-3p or silenced PVT1 was detected by RT-qPCR and western blotting assays. (g) After subcellular fraction, PVT1, miR-1301-3p, KLF7 expression was detected by RT-qPCR. (h) Enrichment of PVT1, miR-1301-3p, KLF7 in Ago2 precipitated products was detected by RIP assay followed by RT-qPCR and was normalized to IgG. *p < 0.05, **p < 0.01, ***p < 0.001.